Drug Profile
TR 8
Alternative Names: TR8Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Trio Medicines
- Class Anti-inflammatories; Antiallergics; Proteins
- Mechanism of Action FPR2 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity; Inflammation
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Allergy in United Kingdom
- 28 Feb 2022 No recent reports of development identified for preclinical development in Inflammation in United Kingdom
- 22 Jan 2018 Preclinical trials in Inflammation in United Kingdom (unspecified route) (Trio Medicines' pipeline, January 2018)